2003
DOI: 10.1128/jvi.77.17.9183-9191.2003
|View full text |Cite
|
Sign up to set email alerts
|

Adenovirus Type 11 Uses CD46 as a Cellular Receptor

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

9
252
2
1

Year Published

2006
2006
2019
2019

Publication Types

Select...
6
3

Relationship

0
9

Authors

Journals

citations
Cited by 309 publications
(264 citation statements)
references
References 71 publications
9
252
2
1
Order By: Relevance
“…CRAd-F35 binds to human CD46 as an infectious receptor. 17,18 Human CD46 is upregulated in malignant tumor cells, including CAR-negative tumor cells, 34 Pre-existing anti-Ad antibodies are a major obstacle for not only gene therapy using a replication-incompetent Ad vector but also virotherapy using CRAds. More than 50% of adults have been reported to possess anti-Ad5 antibodies.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…CRAd-F35 binds to human CD46 as an infectious receptor. 17,18 Human CD46 is upregulated in malignant tumor cells, including CAR-negative tumor cells, 34 Pre-existing anti-Ad antibodies are a major obstacle for not only gene therapy using a replication-incompetent Ad vector but also virotherapy using CRAds. More than 50% of adults have been reported to possess anti-Ad5 antibodies.…”
Section: Discussionmentioning
confidence: 99%
“…16 In the present study, in order to examine the antitumor effects of CRAd-loaded carrier cells on CAR-positive and -negative cells, CRAd-loaded carrier cells were prepared by infection with a conventional CRAd composed of Ad5 or a fiber-substituted CRAd in which fiber proteins are substituted with those of Ad serotype-35 (Ad35) (CRAd-F35). Species-B Ads, including Ad serotypes 3, 11 and 35, recognize human CD46 as a receptor, 17,18 leading to efficient infection of CAR-negative cells with CRAd-F35. Carrier cells loaded with CRAd-F35 showed efficient antitumor effects on not only CAR-positive tumor cells but also CAR-negative tumor cells, although carrier cells infected with a conventional CRAd showed efficient lysis of only CAR-positive cells.…”
Section: Introductionmentioning
confidence: 99%
“…Complement regulatory protein CD46 has been shown to be a cellular receptor for subgroup B viruses. [31][32][33][34] CD46 is highly expressed on many different tumor types including pancreatic cancer. The high expression of this receptor may offer a growth advantage to cancer cells by protecting them from complement damage.…”
Section: Discussionmentioning
confidence: 99%
“…cellular receptor other than CAR, was first accomplished by Krasnykh et al 64 These vectors display CARindependent tropism by virtue of the natural diversity in receptor recognition found in human subgroup B and D fibers. 65 In this regard, primary receptors for subgroup B Ads have been recently identified, including the complement regulatory protein CD46, [66][67][68][69] CD80 and CD86, 70 although an additional unknown receptor is postulated. 67 Subgroup D Ad receptors include CD46 and a(2-3)-linked sialic acid, a common element of glycolipids.…”
Section: Adenovirus Targeting Via Genetic Modification: Fibermentioning
confidence: 99%